Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Trial Profile

Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 11 May 2017

At a glance

  • Drugs Sirolimus (Primary) ; Antineoplastics
  • Indications Renal transplant rejection
  • Focus Adverse reactions
  • Acronyms PROSKIN
  • Most Recent Events

    • 27 Mar 2009 New trial record
    • 27 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top